natalizumab

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

TYSABRI — BIOGEN IDEC, approved 2025-03-18 (BLA125104).

Most reported adverse events (US / FAERS)

132,149 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

19,547

multiple sclerosis relapse

16,860

headache

9,971

multiple sclerosis

9,736

Medicines containing this active substance

3 medicines

Natalizumab Elan Pharma

Refused

🇺🇸 Also approved in the US (FDA)

TYSABRI — BIOGEN IDEC, approved 2025-03-18 (BLA125104).

Most reported adverse events (US / FAERS)

132,149 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

19,547

multiple sclerosis relapse

16,860

headache

9,971

multiple sclerosis

9,736

gait disturbance

9,498

fall

8,032

asthenia

8,005

memory impairment

7,946

malaise

7,363

drug ineffective

6,896

urinary tract infection

6,299

pain

5,957

balance disorder

5,693

hypoaesthesia

5,419

pain in extremity

4,927